Despite these apparently mucosal inflammation-stimulating properties, a protective role for Th17 cells is supported by the observation that anti-IL-17A monoclonal antibody treatment aggravates DSS-induced colitis and that blockade of IL-17A in colitis of IL-10 knockout mice does not reduce disease in the absence of IL-6 neutralization [34, 35]. This evidence concerns the gene IL10 and colitis.